GSKGlaxoSmithKlineRunning, no new patients
A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202
Neoplasms, Head and Neck
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 316 (final count)
- Started
- Nov 14, 2023
- Main results expected
- Sep 10, 2026
- Fully finished
- Dec 31, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Confirmed Objective Response Rate (ORR) compared between Sub studies and Dostarlimab monotherapy
Measured over: Up to approximately 24 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06062420 · record last updated 2026-09-24 · checked 2026-11-09 15:47 UTC